Monday, February 10, 2025

Esketamine Leads in Enhancing Work Productivity for Depression Patients

Similar articles

A recent analysis from the ESCAPE-TRD trial highlights esketamine nasal spray as a more effective treatment than quetiapine extended release in mitigating work productivity loss among adults battling treatment-resistant depression (TRD).

Table of Contents

Subscribe Weekly Market Access News

* indicates required

Study Design and Methodology

The trial encompassed 321 employed adults with TRD, randomly assigned to receive either esketamine (56/84 mg) or quetiapine (150-300 mg), both in combination with an oral antidepressant. Over a 32-week period, participants’ work productivity was evaluated using the Work Productivity and Activity Impairment questionnaire, with assessments made at weeks 8, 16, 24, and 32. The analysis focused on changes in productivity loss and associated costs, utilizing mixed models for repeated measurements to determine the differences between the two treatment groups.

Results and Economic Implications

Findings revealed that by week 8, patients receiving esketamine experienced a 30.3 percentage point reduction in work productivity loss, compared to a 17.3 percentage point decrease among those on quetiapine, resulting in a significant mean difference of 13.0 points. This improvement translated to weekly cost savings of $363 for the esketamine group versus $207 for the quetiapine group. By week 32, the esketamine cohort maintained superior gains, with a 45.3 percentage point reduction in productivity loss against a 32.5 percentage point decline in the quetiapine group, leading to additional cost savings per week.

• Esketamine significantly outperforms quetiapine in reducing work productivity loss among TRD patients.
• The greater reduction in productivity loss with esketamine corresponds to higher weekly cost savings, benefiting both patients and employers.
• These findings suggest that esketamine may be a more economically viable option for managing TRD in the workforce.

Esketamine nasal spray emerges as a superior treatment option for employees grappling with treatment-resistant depression, offering substantial improvements in work productivity and economic benefits. Employers and healthcare providers might consider esketamine as a strategic intervention to enhance workforce well-being and reduce productivity-related costs. Future research could further explore long-term outcomes and the broader economic impacts of adopting esketamine in varied occupational settings.

Source


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article